UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2150-8
Program Prior Authorization/Medical Necessity
Medication Palynziq™ (pegvaliase-pqpz)
P&T Approval Date 9/2018, 7/2019, 7/2020, 6/2021, 7/2021, 7/2022, 7/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Palynziq is a phenylalanine-metabolizing enzyme indicated to reduce blood phenylalanine
concentrations in adult patients with phenylketonuria who have uncontrolled blood phenylalanine
concentrations greater than 600 micromol/L on existing management.
2. Coverage Criteriaa:
A. Initial Authorization
1. Palynziq will be approved based on all of the following criteria:
a. Diagnosis of phenylketonuria (PKU)
-AND-
b. Patient is actively on a phenylalanine-restricted diet
-AND-
c. One of the following:
(1) Patient has a contraindication to saptropterin (list reason)
-OR-
(2) History of failure or intolerance to sapropterin therapy (document date of trial and
list reason for therapeutic failure or intolerance) as determined by a one- to four-
week trial of sapropterin
-AND-
d. Physician attestation that the patient will not be receiving Palynziq in combination with
sapropterin dihydrochloride
-AND-
e. Submission of medical records (e.g., chart notes, laboratory values) documenting that the
patient has a blood phenylalanine concentration greater than 600 micromol/L
Authorization will be issued for 12 months.
© 2024 UnitedHealthcare Services Inc.
1
B. Reauthorization
1. Palynziq will be approved based on all of the following criteria:
a. Patient is actively on a phenylalanine-restricted diet
-AND-
b. One of the following:
(1) Submission of medical records (e.g., chart notes, laboratory values) documenting that
the patient has a blood phenylalanine concentration less than 600 micromol/L
-OR-
(2) Submission of medical records (e.g., chart notes, laboratory values) documenting
that the patient has achieved a 20% reduction in blood phenylalanine concentration
from pre-treatment baseline
-OR-
(3) Patient is in initial titration/maintenance phase of dosing regimen and dose is being
titrated based on blood phenylalanine concentration response up to maximum labeled
dosage of 60 mg once daily
-AND-
c. Submission of medical records (e.g., chart notes, laboratory values) documenting that the
patient is not receiving Palynziq in combination with sapropterin dihydrochloride
[Prescription claim history that does not show any concomitant sapropterin
dihydrochloride claim within 60 days of reauthorization request may be used as
documentation.]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may also be in place.
© 2024 UnitedHealthcare Services Inc.
2
4. References:
1. Palynziq [package insert], Novato, CA: BioMarin Pharmaceutical Inc.; November 2020.
2. Vockley et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline.
American College of Medical Genetics and Genomics Practice Guidelines. Genetics in Medicine
2014;16 (2):188-200.
3. Hydery T, Coppenrath VA. A Comprehensive Review of Pegvaliase, an Enzyme Substitution
Therapy for the Treatment of Phenylketonuria. Drug Target Insights.
2019;13:1177392819857089. Published 2019 Jun 21.
Program Prior Authorization/Medical Necessity - Palynziq (pegvaliase-pqpz)
Change Control
9/2018 New program
7/2019 Annual review with no change to coverage criteria.
7/2020 Annual review with no change to coverage criteria.
6/2021 Added history of failure, contraindication, or intolerance to sapropterin
dihydrochloride to criteria. Updated titration criteria in re-authorization.
Updated reference.
7/2021 Updated contraindication, failure, intolerance criteria.
7/2022 Annual review with no change to coverage criteria.
7/2023 Annual review with no change to coverage criteria.
7/2024 Annual review. Updated authorization durations to 12 months. Updated
references.
© 2024 UnitedHealthcare Services Inc.
3